ABSTRACT
Objetive:To analyze the clínical and bacteriologicalefficacy of mupirocina in the treatment of pediatric patients with skin and solf tissue infectons. Design : Prospective, open, non-comparative clinical trial. Materials and methods: Patiens between 6 months and 12 years old with the clinical and bacteriological diagnosis of a skin of soft tissue infection were included in this trial. Material from the affected site was obtained for culture and susceptibility testing using the kirby - Bauer techique. All the patients were treated with topical mupirocin for 7 days. Follow up visits for clinical evaluations and adverse events were perform during (day 3) and at the end of therapy (day 7-8). Results: From 32 patients enrolled, 23 were considered evaluable. The initial diagnosis were impetigo (29 cases) and pyodermitis (3 cases). The ethiologic agents obtained from the 23 evaluable patients were S. aureus (14), S pyogenes (2), S. aureus and S. Pyogenes (1), Candida albicans (1) and Klebsiella (2). 87.7 porcent (13/5), Of the S. aureus strains and 100 porcent (2/2) of the S. pyoenes strains were mupirocin susceptible. The 2 klepsiella sp. strains were mupirocin resistant. Twenty of the 23 evaluable patients (87 porcent) were considered cured or improved at the end of therapy. Conclusion: The results of this clinical trial, together with other larger trials, suggest that topical mupirocin is a valid and safe alternative for this treatment of pediatric patients with skin and soft tissue infectious